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Abstract: Somatostatin, a polypeptide hormone of 14 or 28 aminoacids, is produced by 
neuroendocrine, inﬂ  ammatory and immune cells. It has multiple inhibitory functions on the 
secretion of various hormones and growth factors and modulates several cellular functions. 
Somatostatin analogues provide an elegant pharmacological principal to modify the high-risk 
form of proliferative diabetic retinopathy. Pilot investigations have provided evidence that octreo-
tide can very effectively suppress new bleeding and stop visual loss in patients who have failed 
conventional photocoagulation therapy. In this cohort, octreotide was found to be a safe treat-
ment modality. The same applies also for thyroid eye disease, in which some non-randomized, 
as well as randomized studies have shown a beneﬁ  cial effect. More potent analogues, like 
SOM230, which are not yet in the market, can be proved to have a better therapeutic outcome 
in such patients and may be considered a safe treatment modality to stop the progression from 
pre-proliferative to proliferative diabetic retinopathy. This is also true for adolescent patients 
with thyroid eye disease, as well as for adults who also suffer from diabetes mellitus.
Keywords: thyroid eye disease, diabetes mellitus, diabetic retinopathy, somatostatin analogues, 
octreotide
Introduction
Progressive damage to the eyes, kidneys, nerves and large vessels represents the major 
threat to health and life of diabetic patients. Therefore, prevention of complications 
should be the main target in these patients. Retinopathy is the most frequent and spe-
ciﬁ  c chronic microvascular complication of diabetes mellitus (DM). It represents a 
major threat to eyesight in the west and is the main cause of blindness among people 
of working age (Kohner 1993). In fact, early signs of retinopathy are apparent in all 
individuals with type 1 diabetes after 20 years and in about 80% of those with type 2 
diabetes of similar duration (Klein et al 1984a, 1984b). It is characterized by the loss of 
pericytes, hypertrophy of basement membrane, microaneurysms formation, increased 
vascular permeability, capillary occlusions, neovascularization and ﬁ  brovascular 
proliferation. The pathogenesis of diabetic retinopathy (DR) is still insufﬁ  ciently 
understood, although some reports have implicated the role of the immune system. 
The ﬁ  nding of antipericyte and antiendothelial cell autoantibodies in the circulation of 
diabetic patients strongly suggests that some autoimmune activity has been involved 
in the early pathophysiology of DR. There is even more evidence that implicates the 
presence of autoimmune mechanisms in the proliferative stage of the disease, such 
as increased vitreous concentration of the interleukin-6 and interleukin-8 in patients 
with proliferative retinopathy (Yuuki et al 2001; Kastelan et al 2007).
In diabetic patients, human leukocyte HLA class II DR and DQ antigen expres-
sion on the retinal vascular endothelial cells, as well as on pigment and nonpigment Clinical Ophthalmology 2007:1(3) 210
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epithelial cells, was found. These antigens are normally 
restricted to immunocompetent cells and play an important 
regulatory role in the immune response. Abnormal expres-
sion of DR and DQ antigens at sites where they do not 
normally exist would result in autoimmunity by converting 
the target cell into a functional antigen – presenting cell. In 
conclusion, there is increasing evidence of the presence of 
some autoimmune processes in the early stages of diabetic 
retinopathy and particularly in its proliferative phases and 
it may be considered as an autoimmune disease (Kastelan 
et al 2007).
Thyroid-associated ophthalmopathy (TAO) or thyroid 
eye disease (TED) is an autoimmune disease and refers 
to the eye changes observed in Graves’ disease (GD). 
The orbital involvement is characterized by lymphocytic 
inﬁ  ltration and edema of retrobulbar tissues, resulting 
in marked swelling of extraocular muscles and orbital 
fat. Due to the increased volume of orbital contents 
the retrobulbar pressure rises, interfering with venous 
drainage (causing lid swelling) and pushing the globe 
forwards (causing proptosis or exophthalmos) (Bahn and 
Heufelder 1993; Krassas and Heufelder 2001). In severe 
cases direct pressure on the optic nerve may result in 
loss of visual functions. The swelling of eye muscles 
hampers muscle motility, associated with double vision. 
The swelling of retrobulbar tissues is largely attributable 
to excessive secretion of glycosaminoglycans (GAGs) 
by orbital ﬁ  broblasts (OFs). In vitro studies have shown 
that OFs are capable of producing GAGs in response to 
various cytokines. These cytokines are probably released 
by inﬁ  ltrating T-lymphocytes in the orbit. Accumulating 
data have led to widely accepted view that the OFs are 
the primary targets of the autoimmune attack. Regard-
ing the nature of the autoantigen consensus has now 
been reached that the full-length thyrotropin stimulating 
hormone (TSH) receptor (TSH-R) is expressed at the 
messenger RNA and protein level in orbital adipose/con-
nective specimens of TED patients but scarcely in that 
of controls (Krassas 2005). The TSH-R is functional, as 
evident from an increase of cAMP in response to TSH. 
Overall, the preponderant concept regarding the nature 
of the autoantigen is that a subpopulation of OFs may be 
the target cells in TED, enabling the preadipocytes, when 
stimulated, to differentiate into nature adipocytes express-
ing increased levels of TSH-R (Krassas and Wiersinga 
2005). Recently, they have been identiﬁ  ed several other 
key antigens namely, ﬂ  avoprotein (FP), G2s, and the 
calcium binding protein calsequesterin (CSQ). It turns 
out the CSQ is expressed 4.6 times more in extraocular 
muscle than in other skeletal muscle, which may partly 
explain the speciﬁ  city of the skeletal muscle reactions in 
GD in the orbit (Gopinath et al 2006).
Recent studies have shown that antibodies against CSQ 
are speciﬁ  c and sensitive markers for eye muscle damage 
in patients with TAO. CSQ antibodies are also markers of 
chronic upper eyelid retraction in patients with GD, Hashi-
moto thyroiditis and transient thyroiditis. Antibodies target-
ing the orbital ﬁ  broblast cell membrane protein collagen XIII 
are linked to the “congestive ophthalmopathy” subtype of 
TAO whereas, in seminal case studies, TSH-R antibodies 
bear no relationship with eye signs. These recent ﬁ  ndings may 
represent an important breakthrough in our understanding of 
ophthalmopathy and may provide reliable clinical tests for 
diagnosis and management purposes (De Bellis et al 2005; 
Gopinath et al 2006).
In summary, TED is an autoimmune disease in which the 
nature of all the autoantigens involved in the autoimmune 
process has not yet been identiﬁ  ed. TSH-R plays a key role, 
enabling the preadipocytes to be differentiated into mature 
adipocytes. Regarding DR, although the pathogenesis is 
not completely understood, it is known that the immune 
system certainly involved in its development, which may 
be the link between the two diseases. The connective tissue 
inﬂ  ammation in the retina and the periorbital space would 
be a common target of SM-as.
The incidence of TED varies among different studies. 
The most accurate data on the incidence of TED is derived 
from a population-based cohort study in Olmsted County, 
Minn, USA (Bartley et al 1995). The overall age-adjusted 
incidence rate was 16.0 cases for women and 2.9 cases 
for men per 100,000 population per year. Peak incidence 
rates were observed in the age groups 40–49 and 60–69 
years. The incidence rates start to increase from the age 
of 20 years. Only 6 out of the 120 incident cases of TED 
observed in this cohort study were in patients below the 
age of 20 years.
SM-as have been used so far in uncontrolled and con-
trolled randomized studies in the treatment of diabetic 
retinopathy (DR) and TED, in different doses. Some studies 
reported encouraging results (Krassas 2001, 2004; Krassas 
and Boboridis 2006).
The aim of this review is to present all new information 
regarding the use of SM-as in the treatment of these two 
appalling diseases and also provide evidence regarding 
the future role of pharmacotherapy in the progression of 
DR and TED.Clinical Ophthalmology 2007:1(3) 211
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Somatostatin and somatostatin 
receptors
Somatostatin (SM) is a polypeptide hormone of 14 (SST-14) 
or 28 (SST-28) amino acids produced by neuroendocrine, 
inﬂ  ammatory and immune cells (Patel 1999). It is synthesized 
as 116-long aminoacid precursor called preprosomatostatin that 
is cleaved by a protease to the prohormone prosomatostatin 
(92 aminoacid long) and ﬁ  nally by endoproteolytic process-
ing to the 14 or 28-aminoacid peptide SM (Dasgupta 2004). 
It has multiple inhibitory functions on the secretion of various 
hormones and growth factors and modulates several cellular 
functions (Table 1) (Siler et al 1974; Unger et al 1978; Bueno 
and Ferre 1982; Krejs 1986; Thorner et al 1990; Makhlouf and 
Schubert 1990; Lewin 1992; Epelbaum et al 1994; Lauder et al 
1997; Bruns et al 2000; Ferjoux et al 2000; Dasgupta 2004).
The biological functions of SM are mediated through soma-
tostatin receptors (SMRs), an evolutionary conserved receptor 
system (82%–96% homology between humans and rodents). 
SMRs are high-afﬁ  nity G-protein coupled receptors expressed 
in target cells (Patel 1999). There are ﬁ  ve functional somatosta-
tin receptors (SMR1-5), and SMR2 has two forms, SMR2A and 
SMR2B, generated by alternative splicing in the cytoplasmic 
tail (SMR2 is the only SMR that has an intron) (Reisine and 
Bell 1995). Ligand (somatostatin) -binding leads to receptor 
phosphorylation (Liu 2003), G-coupled protein activation and 
receptor internalization (Hoﬂ  and and Lamberts 2003).
Signal transduction downstream 
somatostatin receptors
All 5 SMR subtypes signal though pertussis toxin-sensitive 
G-protein coupling that leads to inhibition of adenyl cyclase and 
lowering of the intracellular c-AMP levels (Lewin 1986; Strnad 
et al 1993). There is also evidence that SMR1, SMR2 and 
SMR5 stimulate phospholipase C (PLC) that leads to increased 
calcium mobilization, SMR1 inhibits the Na+/H+ exchanger, 
SMR1, SMR2, SMR3 and SMR4 activate protein tyrosine 
phosphatases, SMR1, SMR3, SMR4 and SMR5 downregulate 
the MAPK/ERK pathway and ﬁ  nally, SMR4 leads to STAT3 
phosphorylation and nuclear translocation (Dasgupta 2004). 
Consequently, there is an extremely complex signal transduc-
tion network that is inﬂ  uenced by SM and the ﬁ  nal outcome 
may rely 1st) on the concentration of the hormone (SM), 2nd) 
on the differential expression of SMR subtypes on the target 
cell, and 3rd) on the coupling of signal transduction pathways 
to the receptors and their crosstalk in each cell type.
Therapeutic approach to diabetic 
retinopathy and thyroid eye disease 
using SM-as
Diabetic retinopathy
Various SM-as have been developed and used in clinical 
practice because the short half-life of SM makes it unsuitable 
for routine treatment (Croxen et al 2004). In the last ﬁ  fteen 
years it has been shown that SM-as might be of therapeutic 
value in the treatment of DR and TED.
Table 2 summarizes the studies published so far, in which 
SM-as have been used in the context of DR. Some studies 
reported effects on the suppression of growth hormone levels, 
stabilization of neovascularizations, resorption of hemor-
rhages and the reduction in the number of microaneurysms. 
In a case report, effective treatment of a macular edema was 
also reported (Kuijpers et al 1998).
Table 1 Physiological functions of somatostatin
Function  Ref
Regulation of hormone secretion  
 Growth  hormone  Thorner et al 1990
 TSH  Siler et al 1974
 Insulin  Unger 1978
 Glucagon  Unger 1978
Gastro-intestinal functions  Lewin 1992
  Inhibition of gastric acid secretion  Makhlouf and Schubert 1990
  Inhibition of intestinal motility  Bueno and Ferre 1982
  Inhibition of absorption of nutritients and ions  Krejs 1986
Vascular effects 
  Inhibition of vascular contractility  Lauder et al 1997
  Inhibition of vascular remodeling  Bruns et al 2000
  Inhibition of angiogenesis  Dasgupta 2004
Inhibition of cellular proliferation  Dasgupta 2004
Neurotransmitter  Epelbaum et al 1994
Modulation of signal transduction and gene expression  Ferjoux et al 2000Clinical Ophthalmology 2007:1(3) 212
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In an uncontrolled trial, Mallet et al (1992) reported 
beneﬁ  cial effects of octreotide (OCT) on the retina as 
regards neovascularization in 4 patients with severe pro-
liferative DR. Kirkegaard et al (1990) investigated the 
possible beneﬁ  cial effect of OCT treatment in patients 
with earlier phases of retinopathy. They didn’t ﬁ  nd any 
difference between patients and controls and suggested that 
perhaps the rate of spontaneous progression in early reti-
nopathy is too low to reveal a beneﬁ  cial effect of OCT with 
a one-year study period. In one uncontrolled study Grant 
et al (1996) reported that OCT did not prevent progression 
of DR in a trial that included severe non-proliferative and 
“non-high risk” proliferative DR patients.
In their second controlled (Grant et al 2000) study the 
same authors studied patients with severe non-proliferative 
DR or early non-high-risk proliferative retinopathy. At this 
stage of DR the likelihood for the need of panretinal photo-
coagulation is high. The SM-as was titrated in 11 patients 
to the maximally tolerated dose for a 15-month period. 
Doses of 200 μg/day up to 5000 μg/day of OCT were used. 
Only one of 22 eyes of the OCT group required panretinal 
photocoagulation, whereas 9 of 24 eyes in the control group 
had to be later treated. The incidence of ocular disease 
progression was only 27% in patients treated with OCT 
compared with 42% in patients with conventional treat-
ment. This study provided evidence that OCT treatment 
retarted progression of advanced retinopathy and delayed 
the time for laser photocoagulation (Grant et al 2000).
In another controlled study, Boehm et al (2001) reported 
the use of OCT in a cohort of diabetic patients with a very 
advanced stage of proliferative DR ie, presence of active prolif-
erations after a full scatter laser treatment (Boehm et al 2001). 
Table 2  Clinical studies in diabetic retinopathy using octreotide (adapted from Reisine and Bell 1995)
Reference  Stage of DR  Diabetic patient  Treatment  Study
    numbers and     duration
   controls   
Kirkegaard et al (1990)  Early diabetic   11 IDDM  Octreotide  1 year
  retinopathy  9 controls  Continuous sc infusion  
      (up to 400 μg/day) 
    7 pts and    
    7 controls    
    completed the    
   study   
Mallet et al (1992)  PDR progressing   4 IDDM  Octreotide  15 months 
  despite   no controls  Continuous sc infusion   (mean)
 photocoagulation    (400  μg/day) (6–20  months)
      Treatment discontinued  
      by decreasing dose by  
     100  μg every month. 
Efthymiou et al (1995)  PDR  2 diabetic   Octreotide  3 months
   patients  SC  100  μgx3/d  
Grant et al (1996)  Severe non-  16 pts  Octreotide  15 months
  proliferative DR, non-  (8 pts: treated  600–3000 μg/day.  
  high risk PDR  8 pts: controls)  Continuous infusion or 
     sc  injection 
Grant et al (2000)  Severe non-  23 pts  Octreotide  15 months
  proliferative DR, early  (11 pts: treated   11 pts: 200–5,000 μg/day  
   non-high risk PDR  12 pts: controls)  sc 12 pts: conventional  
     diabetic  treatment. 
    
      11 treated patients and  
      7/12 control patients  
      given thyroxine  
     replacement. 
Boehm et al (2001)  High-risk PDR, after   9 patients  Octreotide  3 years
  photocoagulation.  (5 IDDM,  Sc injection 100 μg tid 
   4  NIDDM)   
    9 controls    
   (3  IDDM,   
   6  NIDDM)   Clinical Ophthalmology 2007:1(3) 213
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A dose of 300 μg/day of OCT was used in 9 patients; 9 patients 
with standard diabetes management served as controls. The 
observation period was the longest ever reported in a trial 
using a SM-analogue for the treatment of DR. After 3 years 
of treatment the incidence of vitreous hemorrhages was 
signiﬁ  cantly lower in the OCT-treated patients. Also, visual 
acuity was preserved and signiﬁ  cantly better over time in the 
OCT-treated group. Only in the OCT group did a regression 
of proliferations occur, as deﬁ  ned by stereoscopic photography 
and angiography (Boehm et al 2001). There were no severe 
side effects or hypoglycemic events. There are also some case 
reports, which have demonstrated that SM-as inhibit vascular 
effusions (Kuijpers et al 1998; van Hagen et al 2000).
Thyroid eye disease
In the last decade it has also been shown, that SM-as might be 
of therapeutic value in the treatment of active TED in adults. 
Table 3 depicts the initial clinical studies in TED using OCT. 
Most of these studies were uncontrolled, not randomized and 
included only small number of patients (Krassas 2004).
In the past 2 years, four double-blind, placebo-controlled 
clinical studies have been published. In the ﬁ  rst (Dickinson 
et al 2004), 50 euthyroid patients (11 males, 39 females, age 
22–74 years, median 50 years) with active TED (CAS   3, 
NOSPECS 2a–5a, of median duration 0.9 years) received either 
30 g LAR or placeboevery 4 weeks for 16 weeks. Both groups 
then received 30 g LAR for weeks 16–32 and were followed-up 
without treatment for a further 24 weeks. Objective assess-
ments included all individual parameters of TED, CAS, and 
derived scores for soft tissue inﬂ  ammation (STI) and ophthal-
mopathy index (OI). During weeks 0–16 there was signiﬁ  cant 
reduction in STI, subjective diplopia, and CAS in LAR-treated 
patients; STI and CAS were also reduced with placebo. 
The OI reduced by −1.12 in the LAR group (p = 0.0017) 
versus −0.23 with placebo (p = 0.33), giving a barely signiﬁ  -
cant treatment effect by Wilcoxon’s rank sum test (p = 0.043), 
but analysis of covariance failed to conﬁ  rm this (p = 0.16). 
During weeks 16–32 there was no signiﬁ  cant change in OI in 
either group. The overall results (weeks 0−32) showed reduc-
tion in STI and CAS in both groups. They concluded that no 
signiﬁ  cant therapeutic effect of octreotide LAR was seen in 
patients with moderately severe TED. The improvement in 
both treated and placebo groups emphasizes that the results 
of open studies must be viewed with caution.
In another study of a long-acting SM-a (16 weeks of long-
acting release formulation of octreotide [octreotide-LAR]), 
which was conducted in 51 patients with mild active TED and 
aimed at preventing deterioration and precluding the need for 
more aggressive therapeutic modalities, such as glucocorti-
coids or radiotherapy, no treatment effect was observed for 
the primary end point (Wemeau et al 2005). The CAS was 
reduced for patients treated with octreotide-LAR, but without 
any signiﬁ  cant difference from the patients receiving placebo. 
However, octreotide-LAR signiﬁ  cantly reduced proptosis (as 
measured by exophthalmometry). This was associated with 
non-signiﬁ  cant differences in favor of octreotide-LAR in a 
series of proptosis-related parameters. These included class 
III grade, opening of the upper eyelid, the difference in ocular 
pressure before primary position and upgaze, and extraocular 
muscle involvement. Evaluating the extraocular muscle volume 
by magnetic resonance imaging showed a non-signiﬁ  cant reduc-
tion. No signiﬁ  cant correlation between the initial uptake of 
octreoscan and the response to treatment was observed.
The inference was that in this study, octreotide-LAR did 
not seem suitable to mitigate activity in mild TED. However 
proptosis, one of the most debilitating symptoms of TED, was 
Table 3 The initial clinical studies in TED using OCT (reproduced from Krassas 2004)
Reference  Type of analog  No. of patients studied  respondents
Chang et al (1992)  Octreotide  6  6
Krassas et al (1995)  Octreotide  12  7
Ozata et al (1996)  Octreotide  10  5
Khoo et al (1995)  Octreotide  8  6
Kung et al (1996)  Octreotide  8  6
Uysal et al (1999)  Octreotide  9  7
Durak et al (1995)  Octreotide  3  0
Krassas et al (1997)  Lanreotide  5  4
Krassas et al (1997)  Lanreotide  5  4
 Octreotide  5  4
Krassas et al (2001)  Long-acting release  2  2
 octreotide
Total   73  51Clinical Ophthalmology 2007:1(3) 214
Krassas et al
signiﬁ  cantly reduced. The sustained effect on proptosis of 
just 16 weeks of octreotide-LAR treatment is an encouraging 
preliminary result in light of the serious lack of therapeutic 
options for this condition.
Very recently a third similar study was published in which 
lanreotide 20 mg every two weeks was used in a randomized 
fashion. A total of 60 patients were investigated. The infer-
ence was that lanreotide had no effect on CAS in patients 
with TED (Chang and Liao 2006).
Finally, one similar randomized, controlled study from 
the Endocrinology Department of Mayo Clinic, Rochester, 
MN, USA has just been published (Stan et al 2006). They 
investigated 29 patients with moderately severe TED. Patients 
received 4 monthly doses of either octreotide LAR (20 mg) or 
saline by im injections. The inference was that CAS improved 
to a greater extend in octreotide-LAR-treated patients than the 
control group. However, this ﬁ  nding may not represent clinical 
beneﬁ  t because patients with higher baseline CAS were overrep-
resented in the treatment group and the control group was small. 
In contrast, treatment-related improvement in eyelid ﬁ  ssure 
width was noted, suggesting that octreotide LAR may be useful 
in the treatment of a subgroup of active thyroid ophthalmopathy 
patients with signiﬁ  cant lid retraction (Stan et al 2006).
Future perspectives of SM-as in the 
treatment of diabetic retinopathy 
and thyroid eye disease
SM-as provide an elegant pharmacological principle to 
modify the high-risk form of proliferative DR (Aiello 
et al 1995). The potential role of these substances may be 
due to suppression of pro-angiogenic molecules, a direct 
inhibition of pro-angiogenic signaling at the cell level, an 
anti-ﬁ  brotic action, thus reducing ﬁ  brovascular formations, 
and at least a partial correction of the systemic GH and 
IGF-I dysregulation (Boehm and Lustig 2002). Data from 
the Boehm study and from other pilot investigations have 
provided evidence that OCT can very effectively suppress 
new bleeding and stop visual loss in patients who have 
failed conventional photocoagulation therapy (Boehm and 
Lustig 2002). In this cohort, OCT was found to be a safe 
treatment modality. It remains to be clariﬁ  ed whether the 
progression from pre-proliferative to proliferative reti-
nopathy can also be stopped by the use of today available 
SM-a or by the use of more potent analogues like SOM230, 
which are not yet available in the market. The latter has, in 
contrast with the so far used analogues, a rather high afﬁ  nity 
for all sst subtypes except ss4 (Table 4) (Bruns et al 2002; 
Croxen et al 2004).
The same applies also for TED in which more potent ana-
logues can also proved to be the treatment of choice in mod-
erately severe cases with DM, as well as in adolescents.
It is thus plausible to assume that SOM230 might be much 
more effective in the treatment of DR and TED.
Clinical research is needed to demonstrate the efﬁ  cacy 
of new SM-as in the treatment of DR and TED. Such studies 
will be proved to be of extremely importance in the pharma-
cotherapy of these two deliberating diseases.
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